Diplosalsalate

Diplosalsalate

SCHEMBL25398

CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 1.00
HSD17B10 Q99714 7/20 1.00
LMNA P02545 1/20 1.00
CYP1A2 P05177 1/20 1.00
CYP2C9 P11712 1/20 1.00
HPGD P15428 5/20 0.86
ALDH1A1 P00352 4/20 0.86
PTGS2 P35354 4/20 0.86
TSHR P16473 2/20 0.86
ESR1 P03372 1/20 0.86
ITGB3 P05106 1/20 0.86
ITGA2B P08514 1/20 0.86
HMGB1 P09429 1/20 0.86
GGT1 P19440 1/20 0.86
PTGS1 P23219 1/20 0.86
BLM P54132 1/20 0.86
NAPRT Q6XQN6 1/20 0.86
TDP1 Q9NUW8 1/20 0.86
MAPK1 P28482 1/20 0.62
MAPT P10636 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Diplosalsalate SCHEMBL30590970 1.00 KDM4E (1.00) KDM4EHSD17B10LMNACYP1A2CYP2C9
SCHEMBL2473332 1.00 KDM4E (1.00) KDM4EHSD17B10LMNACYP1A2CYP2C9
Diplosalsalate SCHEMBL25303461 0.98 KDM4E (0.97) KDM4EHSD17B10LMNACYP1A2CYP2C9
Aspirin SCHEMBL29350479 0.93 KDM4E (1.00) KDM4EHSD17B10LMNACYP1A2CYP2C9
Aspirin SCHEMBL10456693 0.93 KDM4E (1.00) KDM4EHSD17B10LMNACYP1A2CYP2C9
Aspirin SCHEMBL1331740 0.93 KDM4E (1.00) KDM4EHSD17B10LMNACYP1A2CYP2C9
Aspirin SCHEMBL7580 0.93 KDM4E (1.00) KDM4EHSD17B10LMNACYP1A2CYP2C9
Aspirin SCHEMBL1353 0.93 KDM4E (1.00) KDM4EHSD17B10LMNACYP1A2CYP2C9
Aspirin SCHEMBL20484785 0.91 KDM4E (0.96) KDM4EHSD17B10LMNACYP1A2CYP2C9
Aspirin SCHEMBL21488922 0.91 KDM4E (0.96) KDM4EHSD17B10LMNACYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 885 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240307283-A1 COMPOSITIONS AND METHODS FOR DECREASING PIGMENTATION THE GENERAL HOSPITAL CORPORATION 2024-09-19 US claimed
CN-118340907-A Polymer conjugates comprising bioactive agents 波利艾克蒂瓦有限公司 2024-07-16 CN claimed
CN-118215461-A Compositions and methods for reducing pigmentation 总医院公司 2024-06-18 CN claimed
EP-4366837-A2 COMPOSITSONS AND METHODS FOR DECREASING PIGMENTATION The General Hospital Corporation (US) 2024-05-15 EP claimed
US-20230285282-A1 OCULAR IMPLANT CONTAINING AN ACTIVE INGREDIENT OCULAR THERAPEUTIX INC (US) 2023-09-14 US claimed
EP-4236943-A1 OCULAR IMPLANT CONTAINING AN ACTIVE AGENT Ocular Therapeutix, Inc. (US) 2023-09-06 EP claimed
WO-2023283554-A2 COMPOSITSONS AND METHODS FOR DECREASING PIGMENTATION THE GENERAL HOSPITAL CORPORATION (US) 2023-01-12 WO claimed
CN-115247192-A Enzymatic preparation technology of acyl/aroyl coenzyme A 中国医学科学院药物研究所 2022-10-28 CN claimed
WO-2022093818-A1 OCULAR IMPLANT CONTAINING AN ACTIVE AGENT OCULAR THERAPEUTIX, INC. (US) 2022-05-05 WO claimed
US-10758626-B2 Polymer conjugate comprising a bioactive agent POLYACTIVA PTY LTD (AU) 2020-09-01 US claimed
EP-0759899-B1 NITRO COMPOUNDS AND THEIR COMPOSITIONS HAVING ANTI-INFLAMMATORY, ANALGESIC AND ANTI-THROMBOTIC ACITIVITIES NICOX SA (FR) 1999-09-15 EP claimed
EP-0931065-A2 NITRIC ESTER DERIVATIVES AND THEIR USE IN URINARY INCONTINENCE AND OTHER DISEASES NICOX S.A. (FR) 1999-07-28 EP claimed
WO-1998022114-A1 A METHOD FOR PROMOTING TISSUE REPAIR DUMEX-ALPHARMA A/S (DK) 1998-05-28 WO claimed
WO-1998009948-A2 NITRIC ESTER DERIVATIVES AND THEIR USE IN URINARY INCONTINENCE AND OTHER DISEASES NICOX S.A. (FR) 1998-03-12 WO claimed
US-5635443-A IMMERSING THE STEM OF CUT FLOWER IN A SOLUTION CONTAINING SURFACTANT, FRAGRANCE, SOLVENT, WATER, ACETYLSALICYLIC ACID OR ACETYLSALICYLICSALICYLIC ACID OR BOTH, SODIUM CHLORIDE, SODIUM BICARBONATE, PLANT FOOD AND HORMONE AND ANTIFOAM AGENT FLORASYNTH, INC. (US) 1997-06-03 US claimed
EP-0759899-A1 NITRO COMPOUNDS AND THEIR COMPOSITIONS HAVING ANTI-INFLAMMATORY, ANALGESIC AND ANTI-THROMBOTIC ACITIVITIES NICOX S.A. (FR) 1997-03-05 EP claimed
WO-1995030641-A1 NITRO COMPOUNDS AND THEIR COMPOSITIONS HAVING ANTI-INFLAMMATORY, ANALGESIC AND ANTI-THROMBOTIC ACITIVITIES NICOX S.A. (FR) 1995-11-16 WO claimed
US-4287174-A CONTAINING A QUATERNARY AMMONIUM CARBOXY ZWITTERIONIC COMPOUND AND AN ANTACID THE PROCTOR & GAMBLE COMPANY (US) 1981-09-01 US claimed
US-4275059-A IN COMBINATION WITH A DIPHOSPHONATE COMPOUND THE PROCTER & GAMBLE COMPANY (US) 1981-06-23 US claimed
EP-0004686-A2 Anti-ulcer composition THE PROCTER & GAMBLE COMPANY (US) 1979-10-17 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10758626-B2 Polymer conjugate comprising a bioactive agent MSN, PAM, PARG KDM4E 3935/4885HSD17B10 3174/4885LMNA 1925/4885
US-20230285282-A1 OCULAR IMPLANT CONTAINING AN ACTIVE INGREDIENT ERBB2, BTK, ERBB3 KDM4E 1064/4885HSD17B10 2167/4885LMNA 4759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.